SEA'S ONLY VACCINE CONFERENCE FROM DISCOVERY TO DELIVERY

Arindam Ray is a medical epidemiologist with about 30 years of experience in public health management particularly in urban health care, population studies, disease surveillance and immunization. Following his tenure under Government of West Bengal, he joined World Health Organization in 2000. He was National Monitoring and Evaluation Focal Person at WHO country office, India before joining Bill & Melinda Gates Foundation in 2014. At the Foundation, India office he looks after new vaccine initiatives, immunization systems, disease surveillance and modelling, Gavi projects and polio legacy work. He represents the Foundation at the global urban immunization workgroup, GAVI Asia-Pacific Regional Work Group, WHO SEAR RITAG, India Expert Committees on Rota Viral Vaccine, Pneumococcal Conjugate Vaccine, HPV vaccine, Typhoid conjugate vaccine and Polio & MR India Expert Advisory Groups.

‍

Dr. Badarulhisam is currently the Chief Scientific Officer at Pharmaniaga Berhad. He is responsible to spearhead product development and regulatory strategies for the company, inclusive of product ideation, development, trial, registration and product life cycle management. Among others, he is currently leading the team for various biopharma and vaccine development program, either through in house development or through technology transfer from several international strategic partners.

Dr Badarulhisam qualified as a Biochemical Engineer. He received his PhD from the Johns Hopkins University, USA and MSc and Advanced Diploma from the University College of London, UK.  His area of expertise is in the fields of Biochemical Engineering and Biotechnology.  Dr. Badarulhisam developed his early career as a lecturer at the Department of Bioprocess Engineering, University Technology of Malaysia and he is still active academically. He has served as a Professor (adjunct) at Chemical Engineering Department, University Putra Malaysia and he is also a member for the Board of Academic Advisory, School of Pharmacy, Universiti Kebangsaan Malaysia and a few other universities. He has served as an industrial advisor to several Bioprocess Engineering Programs in major universities in Malaysia and co supervises Masters and PhD students in various aspects of Biopharmaceutical Plant Design, Biologics Drug Development and Process Optimizations.

Zainab Sadat is a senior healthcare executive with over two decades of global leadership experience across pharmaceuticals, vaccines, and diagnostics. As General Manager for Southeast Asia and India at Sanofi, she spearheads strategic growth initiatives across diverse and rapidly evolving markets. Prior to Sanofi, Zainab held executive roles at Abbott and GSK. She is recognized as a transformative leader, known for her expertise in P&L management, digital transformation, successful product launches and passion for people development. Her leadership focuses on advancing healthcare access and driving innovation across emerging markets, impacting millions of lives throughout the Asia-Pacific region

Meenu Batolar is the Asia Pacific Lead for Global Regulatory Affairs at CEPI, where she drives regulatory collaboration and preparedness strategies for future epidemics and pandemics. With leadership experience across Takeda Vaccines, Sanofi Pasteur, Biogen Idec, Baxter, and UCB, she has built deep expertise in Regulatory Affairs, Pharmacovigilance, Compliance, and Government Affairs across the Asia Pacific region. Meenu played a pivotal role in securing the first licensure of Inactivated Polio Vaccines (IPV) in India and advancing dengue vaccine registrations across Asia. An AIIMS New Delhi pharmacology graduate, she is recognized for pioneering regulatory innovations, fostering public health partnerships, and championing vaccine access. Beyond work, she enjoys storytelling, travel, fitness, yoga, and Reiki.

Neni Nurainy, Ph.D., joined Bio Farma in 1997. She currently serves as the Head of the Translational Development of Life Science Products Division at PT Bio Farma, Indonesia. She graduated from the Pharmacy Department at the Bandung Institute of Technology in 1996, and later completed her postgraduate studies, earning a Ph.D. in Biomedical Science from the University of Indonesia in 2005. Driven by her interest in vaccine development, she pursued a Postdoctoral Research Fellowship at the Department of Microbiology and Immunology at the University of Melbourne in 2009.

Dr. Nurainy’s extensive experience in vaccinology includes the development of the Haemophilus influenzae type b conjugate, Hepatitis B, and COVID-19 vaccines. Her current research and development work focuses on a new TB vaccine, mRNA and viral vector technology, adjuvants, delivery systems, and therapeutic proteins. Additionally, she serves as the co-lead for the CEPI Vaccine Manufacturing Facility Network at Bio Farma. She has authored and co-authored numerous peer-reviewed articles published in reputable international journals and holds several national patents in the field of Hep B recombinant protein.

Indriana Permatasari is a Project Head with more than 19 years of experience in clinical research and drug development, covering Phase 1–4 clinical trials in local, regional, and global settings. She has extensive expertise in project management, clinical operations, regulatory compliance, risk management, and stakeholder engagement. Throughout her career at International Vaccine Institute and IQVIA, she has successfully led multidisciplinary teams, managed global clinical trial portfolios across multiple countries, and supported regulatory inspections and sponsor audits. With a strong background in vaccines, oncology, nutrition, and infectious diseases, she is recognized for her leadership, adaptability, problem-solving abilities, and commitment to delivering high-quality project outcomes.

As the Director of the Mahidol Vivax Research Unit (MVRU) at the Faculty of Tropical Medicine, Mahidol University, I lead a research team of > 30 staff including junior scientists, postdoctoral fellows and graduate students.  We are one of a few research groups that consistently work on the P. vivax parasite, which cannot be continuously cultured in laboratory.  I have established the first field-based membrane feeding assay for evaluation of transmission blocking immunity against P. vivax.  This method has been used to evaluate vaccine candidates and naturally acquired immunity in endemic populations. Our capacity to conduct research on P. vivax biology has contributed to the progress on P. vivax transmission blocking vaccine.  The first P. vivax human challenge study in Thailand has been established by my team in collaboration with Oxford University.  This study will increase our capacity to evaluate the new vaccine candidates and drugs against all stages of P. vivax.  To better understand the immune response against malaria infection is important for better vaccine design and evaluation.

Indra Rudiansyah is the Project Lead for the mRNA Vaccine Programme at Bio Farma, Indonesia, working with WHO, the Medicine Patent Pool (MPP) and CEPI to build national and regional mRNA manufacturing capabilities and strengthen outbreak preparedness.

He holds a D.Phil. in Clinical Medicine from the University of Oxford, where he specialised in malaria vaccine development and contributed to the clinical advancement of the ChAdOx1 nCoV-19 vaccine during the COVID-19 pandemic. He has also supported the COVAX Facility on vaccine policy and product monitoring.

In addition, Indra is a Research Assistant at Impact Global Health for the G-FINDER project, tracking investments in EIDs, neglected diseases and SRH.

His Ph.D. program concentrates on the mechanism of how exosomes facilitate Flaviviridae vector-borne diseases transmission from arthropods to host.  As the pioneer of this novel theory, he published on several top journals (PNAS, EMI, PLoS Pathg, EMBO etc.). As an ORISE postdoc fellow worked at the FDA, he became an expert on live attenuated rubella vector vaccine expressing antigens of HIV, RSV and Malaria. After back to China, he worked as the TA head & CSO assistant at CNBG-Virogin, was responsible for POC stage research of mRNA vaccine for infectious disease. Now he is working as CEO scientific assistant at Abogen Biosciences, responsible for scientific collaboration and discussion.

With over three decades of leadership experience in the pharmaceutical and biotech industry, he currently serves as Deputy Director at Serum Institute of India, overseeing business across Southeast Asia, Nepal, Bhutan, Australia, and New Zealand. Since joining Serum Institute in 2005, he has built extensive expertise in market access, country operations, business growth, and regulatory acceleration across diverse international markets.

Xiaoyuan Zhao positions an International Clinical Project Management Expert in the R&D Division at CanSino Biologics Inc., a leading Chinese vaccine manufacturer. With five years of dedicated experience in vaccine clinical trials, she has led multiple overseas trials across Indonesia, Malaysia, Thailand, Canada, and Australia. Currently, she is managing Phase 1/2 infants’ polio vaccine trial in Indonesia.

Mohd Fadhil Razmi is the Head of the Vaccine and Logistics Cluster at the Malaysia Vaccine Project Office (MVPO), Ministry of Science, Technology and Innovation (MOSTI). With nearly 20 years of experience in the Malaysian public service, he has worked across policy, administration, finance, and project management, including nearly nine years with the Ministry of Health Malaysia. At MVPO, he supports the implementation of Malaysia’s National Vaccine Development Roadmap (NVDR), focusing on vaccine development and manufacturing, logistics, capacity building, and international collaboration. He coordinates engagement with government agencies, research institutions, industry, and international partners to strengthen Malaysia’s vaccine ecosystem and preparedness.

Dr. Ahmad is a senior public health and management professional with over 30 years of national and international experience in strategic planning, programme design, implementation, partnerships, capacity building, resource mobilisation, and policy advocacy. His expertise spans immunization, maternal and child health, sexual and reproductive health, family planning, HIV/AIDS, nutrition, digital health, and health systems strengthening. He has led large, complex health programmes with governments, UN agencies, NGOs, donors, and private sectors across South and Central Asia and Africa. He currently supervises Bangladesh’s National Digital Health Services and serves as Chair of the Gavi CSO Steering Committee.

An experienced and versatile Ph.D. pharmaceutical R&D/Scientific Affairs professional with about 15 years of experience including 8 years as Founder and CEO of Pinotbio, Inc. Experience in drug discovery programs in the areas of oncology – 2 INDs and many on-going pre-clinical programs. Formerly patent examiner in Korea Intellectual Property Office (KIPO) and possesses extensive knowledge about patents and related matters. Has led many scientific evaluations and due diligence of licensing/partnership opportunities in the academic institute and industry in the field of oncology. Extensive knowledge and understanding of drug discovery and preclinical development, especially related to Antibody-Drug Conjugate (ADC) platforms and ADC candidates. Deep understanding of medicinal and process chemistry, especially related with camptothecin payloads and ADC linkers.

Currently, CEO of Pinotbio, Inc. – a South-Korea based biotech company focusing on the discovery and development of novel ADC platforms.

Dr. Seyed Reza Banihashemi is a Ph.D. in Clinical Immunology from Tarbiatmodares University in Tehran, Iran, and also a Vaccinologist. He is currently the deputy of R&D and Assistant Professor of the Immunology Department at Razi Vaccine and Serum Research Institute. He has extensive experience in vaccine research and development, with a focus on immune responses bacterial and viruses’ vaccines. He is main researcher and developer of the Razi Cov-Pars protein recombinant COVID-19 vaccine (the first intranasal covid-19 vaccine) and he is the manufacturer of the Nano emulsion adjuvant system related to this vaccine. He has published several research papers on topics such as vaccine development, immune response evaluation, and adjuvant and drug delivery system. He is also a reviewer for prestigious scientific journals in the field of microbiology and immunology.

Dr. Nicholas Lim is the Sanofi Medical Head for RSV Vaccines in the Southeast Asia & India region and Singapore Country Medical Head, where he supports bridging therapeutics from bench to bedside. His responsibilities include building partnerships with healthcare professionals and healthcare bodies to drive equitable access to innovations that prevent infectious diseases and strengthen public health systems. Previously, Dr. Lim was Medical Head for Specialty Care in Southeast Asia at Sanofi and led medical teams supporting Eli Lilly and Moderna’s innovation portfolios. He is recognised for his patient-centric approach and extensive pharmaceutical industry experience, advancing healthcare across rapidly evolving systems to impact millions of lives.

Claire Chong is a Technical Application Manager at Tofflon, supporting biopharmaceutical and vaccine manufacturing projects across Southeast Asia. With over 10 years of experience in bioprocessing, she has worked across upstream and downstream processing, single-use technologies, process scale-up and technology transfer. Her current focus is on enabling flexible and scalable manufacturing through integrated bioprocess solutions, supporting customers from early-stage development through commercial production. She works closely with vaccine manufacturers in the region on facility and process implementation, with particular emphasis on modular manufacturing, single-use technologies and GMP-ready scale-up.